TOP TIERMARKET NEWSWIRE
Movers explained · 2026-10-02

Archived explainer. For the current picture see today's NKTR page.

Why Is NEKTAR THERAPEUTICS (NKTR) Stock Down Today?

By the Top Tier Newswire AI Desk · October 2, 2026 at 11:40 AM ET · reviewed against 17 wire stories

NEKTAR THERAPEUTICS (NKTR) is down -5.64% in the latest session. Our newswire has captured 17 stories on NKTR across 11 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Why NKTR stock is down today

Nektar Therapeutics (NKTR) shares fell 5.64% to $44.34 on Thursday, marking a sharp decline amid the release of new mid-stage trial data for its hair loss candidate, rezpegaldesleukin. The stock opened at $47.00 and hit a session high of $47.40 before falling to a low of $44.27. The drop follows mixed reactions to the clinical data and growing skepticism from investors.

What Happened

Nektar announced data from two trials of rezpegaldesleukin in alopecia and eczema, triggering immediate market response. The stock fell -21.6% in one session earlier in the week, and the new data has not reversed that trend. Analysts from H.C. Wainwright and Jefferies have commented on the selloff, with the former calling it overdone and the latter calling it unwarranted. Despite some positive assessments from William Blair, which highlighted the drug's durability edge, the broader market has remained bearish. The CEO and Chief Research and Development Officer both sold shares on August 18, signaling caution from within the company.

What The Data Shows

The stock has lost 25.6% over the last eight sessions, falling from $66.41 to $49.41. The current price of $44.34 is near the 52-week low of $33.40. Trading volume has been 1.1 million shares, slightly above the 3-month daily average. Insiders have sold $43,000 worth of shares in the last 90 days, with no insider buys recorded. The stock has printed 20 fresh 52-week lows on October 2, underscoring the bearish sentiment.

What To Watch

The company is scheduled to host a shareholder and analyst call on October 1, 2026, which may provide further insight into the drug development pipeline and management's strategy. Investors should monitor the breadth of coverage and analyst reactions in the coming days for potential shifts in sentiment.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

NKTR by the numbers

Last: $44.34Session: -5.64%7 sessions: -24.42%Coverage: 17 stories / 11 sourcesAI sentiment: 49/100 (mixed)Mkt cap: $2.1B52w: $33.40 to $109.00
NKTR · Oct 2 session (5-min) · -6.53% vs prior close · updated 8:58 PM ET
$43.17$45.35$47.53prev close $46.99$43.927:30 AM10:36 AM1:42 PM4:48 PM7:55 PM7:30 AM · $47.007:45 AM · $46.967:50 AM · $46.977:55 AM · $46.988:00 AM · $46.908:05 AM · $46.708:10 AM · $46.608:20 AM · $46.608:30 AM · $47.238:45 AM · $47.139:05 AM · $47.109:20 AM · $47.309:25 AM · $47.109:30 AM · $46.829:35 AM · $46.289:40 AM · $45.919:45 AM · $45.919:50 AM · $45.939:55 AM · $46.3310:00 AM · $46.3110:05 AM · $46.1410:10 AM · $45.9210:15 AM · $45.8010:20 AM · $46.2410:25 AM · $45.8810:30 AM · $46.0210:35 AM · $46.2610:40 AM · $46.1110:45 AM · $45.9810:50 AM · $46.0810:55 AM · $45.6711:00 AM · $45.9011:05 AM · $45.6211:10 AM · $45.5811:15 AM · $45.0511:20 AM · $44.7111:25 AM · $44.5911:30 AM · $44.7211:35 AM · $44.3711:40 AM · $44.2411:45 AM · $44.4411:50 AM · $44.3411:55 AM · $44.1812:00 PM · $44.5212:05 PM · $44.5912:10 PM · $44.5112:15 PM · $44.6812:20 PM · $44.4212:25 PM · $44.5412:30 PM · $44.7712:35 PM · $44.5412:40 PM · $44.5512:45 PM · $44.4412:50 PM · $44.3612:55 PM · $44.301:00 PM · $44.081:05 PM · $44.221:10 PM · $44.071:15 PM · $44.111:20 PM · $43.951:25 PM · $44.241:30 PM · $44.161:35 PM · $44.211:40 PM · $44.251:45 PM · $44.211:50 PM · $44.361:55 PM · $44.382:00 PM · $43.932:05 PM · $43.832:10 PM · $43.832:15 PM · $43.702:20 PM · $43.532:25 PM · $43.592:30 PM · $43.592:35 PM · $43.762:40 PM · $43.872:45 PM · $43.972:50 PM · $43.902:55 PM · $43.813:00 PM · $43.653:05 PM · $43.903:10 PM · $43.743:15 PM · $44.073:20 PM · $43.943:25 PM · $43.853:30 PM · $44.303:35 PM · $44.043:40 PM · $43.853:45 PM · $43.833:50 PM · $43.823:55 PM · $43.614:00 PM · $44.894:30 PM · $43.694:35 PM · $43.585:20 PM · $43.586:30 PM · $43.406:50 PM · $43.407:55 PM · $43.92
AI sentiment, last 36h · averaged over 17 stories · 49/100 neutral
AI sentiment 49/100 (neutral)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishThe Fly · sentiment 29 · Nektar falls -21.6%The Fly · 29Nektar falls -21.6%The Fly · sentiment 63 · William Blair says rezpeg data a positive for NektarThe Fly · 63William Blair says rezpeg data a positive for NektarSeeking Alpha · sentiment 50 · Nektar Therapeutics (NKTR) Shareholder/Analyst Call TranscriptSeeking Alpha · 50Nektar Therapeutics (NKTR) Shareholder/Analyst Call TranscriptSeeking Alpha · sentiment 34 · Nektar drops after new mid-stage trial data for hair loss drugSeeking Alpha · 34Nektar drops after new mid-stage trial data for hair loss drugThe Fly · sentiment 38 · Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says JefferiesThe Fly · 38Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says JefferiesStocktwits News · sentiment 38 · NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability EdgeStocktwits News · 38NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Dura…The Fly · sentiment 58 · Nektar selloff yesterday overdone, says H.C. WainwrightThe Fly · 58Nektar selloff yesterday overdone, says H.C. WainwrightInvesting.com Analyst Ratings · sentiment 56 · H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia dataInvesting.com Analyst Ratings · 56H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data
49d agoInvesting.com Analyst RatingsBULLISH 56Analyst

H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data

H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data

49d agoThe FlyBULLISH 58Analyst

Nektar selloff yesterday overdone, says H.C. Wainwright

49d agoStocktwits NewsBEARISH 38Product/PR

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar on Thursday announced data from two trials of its drug rezpegaldesleukin in alopecia and eczema.

49d agoThe FlyBEARISH 38General

Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says Jefferies

50d agoSeeking AlphaBEARISH 34Product/PR

Nektar drops after new mid-stage trial data for hair loss drug

Nektar Therapeutics (NKTR) stock dips as the company posts new mid-stage trial data for its hair loss candidate, rezpegaldesleukin. Read more here.

50d agoSeeking AlphaNEUTRAL 50General

Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript

Nektar Therapeutics (NKTR) Shareholder/Analyst Call October 1, 2026 8:00 AM EDTCompany ParticipantsVivian WuMary Tagliaferri - Chief Medical OfficerJonathan...

50d agoThe FlyBULLISH 63Analyst

William Blair says rezpeg data a positive for Nektar

50d agoThe FlyBEARISH 29General

Nektar falls -21.6%

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on NKTR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier NKTR move explainers: 2026-10-02 · 2026-10-01 · 2026-09-23